×
About 190 results

ALLMedicine™ Best Disease Center

Research & Reviews  67 results

Cell Collection to Study Eye Diseases
https://clinicaltrials.gov/ct2/show/NCT01432847

Aug 9th, 2022 - This study will establish a repository of biospecimens to generate induced pluripotent stem (iPS) cells, which will be used to determine molecular mechanisms for potentially blinding eye diseases including but not limited to: Best Vitelliform Dyst...

Adult-onset bestrophinopathy mistaken as central serous chorioretinopathy.
https://doi.org/10.1080/13816810.2022.2053994
Ophthalmic Genetics; Khan AO, Ghazi NG

Mar 22nd, 2022 - To highlight cases of adult-onset bestrophinopathy mistaken as central serous chorioretinopathy (CSCR). Retrospective case series. Two unrelated adult males (54 years old and 43 years old) with serous macular detachments were managed as CSCR. One ...

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
https://clinicaltrials.gov/ct2/show/NCT02440464

Feb 1st, 2022 - The study is designed as a Phase II, multi-center double-blind trial that randomizes patients with high risk Multiple Myeloma to Ixazomib maintenance or placebo 60-120 days after allogeneic HSCT. The primary objective of this randomized trial is t...

Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.
https://clinicaltrials.gov/ct2/show/NCT02162953

Jan 6th, 2022 - The PI on this proposal has been studying BEST1 and the protein encoded (Best1) since its discovery in 1998. Best1 is an integral membrane protein that in the eye is expressed only by retinal pigment epithelial (RPE) cells where it is localized to...

Best disease presenting as subretinal pigment epithelium hyperreflectivite lesion on sp...
https://doi.org/10.1177/11206721211055961
European Journal of Ophthalmology; Sayman Muslubas I, Arf S et. al.

Nov 23rd, 2021 - To report clinical and multimodal imaging features of Best disease in patients presenting with subretinal pigment epithelium hyperreflective lesions. Retrospective study. Clinical examination findings and multimodal imaging features, including col...

see more →

Clinicaltrials.gov  4 results

Cell Collection to Study Eye Diseases
https://clinicaltrials.gov/ct2/show/NCT01432847

Aug 9th, 2022 - This study will establish a repository of biospecimens to generate induced pluripotent stem (iPS) cells, which will be used to determine molecular mechanisms for potentially blinding eye diseases including but not limited to: Best Vitelliform Dyst...

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
https://clinicaltrials.gov/ct2/show/NCT02440464

Feb 1st, 2022 - The study is designed as a Phase II, multi-center double-blind trial that randomizes patients with high risk Multiple Myeloma to Ixazomib maintenance or placebo 60-120 days after allogeneic HSCT. The primary objective of this randomized trial is t...

Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.
https://clinicaltrials.gov/ct2/show/NCT02162953

Jan 6th, 2022 - The PI on this proposal has been studying BEST1 and the protein encoded (Best1) since its discovery in 1998. Best1 is an integral membrane protein that in the eye is expressed only by retinal pigment epithelial (RPE) cells where it is localized to...

A Study for Older Adults With Acute Lymphoblastic Leukaemia
https://clinicaltrials.gov/ct2/show/NCT01616238

Feb 15th, 2019 - The study will establish baseline expectations for Event Free Survival (EFS), Overall Survival (OS), MRD responses and quality of life measures for older patients of all ages and pre-morbid states; disclose how best to use knowledge of pre-morbid ...

see more →

News  5 results

Durvalumab Plus Olaparib or Cediranib Leads to Disease Stabilization in Leiomyosarcoma
https://www.onclive.com/view/durvalumab-plus-olaparib-or-cediranib-leads-to-disease-stabilization-in-leiomyosarcoma

Sep 23rd, 2021 - The combination of durvalumab (Imfinzi) plus either olaparib (Lynparza) or cediranib resulted in disease stabilization of 33% in patients with leiomyosarcoma (LMS), which supports further immunophenotype characterization in this disease, according...

Clinical Edge Commentary: RA June 2021
https://www.mdedge.com/rheumatology/article/241427/rheumatoid-arthritis/clinical-edge-commentary-ra-june-2021
Arundathi Jayatilleke, MD

Jun 11th, 2021 - Arundathi Jayatilleke, MD In the approach to treatment of patients with rheumatoid arthritis (RA), methotrexate monotherapy is often followed by addition of a biologic disease modifying anti-rheumatic drugs (bDMARDs) for best disease outcomes. Com.

CAR-T Therapy Treatment Variables
https://www.onclive.com/view/car-t-therapy-treatment-variables

Apr 2nd, 2021 - Transcript: Caron Jacobson, MD: In our series, we didn’t do the propensity score analysis, so we weren’t able to subtract the high-risk disease characteristics. But we also saw a decrease in overall survival and an increase in nonrelapse morta...

Dr. Ramchandran on Considerations for Palliative Care in Thoracic Cancers
https://www.onclive.com/view/dr-ramchandran-on-considerations-for-palliative-care-in-thoracic-cancers

Dec 4th, 2020 - Kavitha Ramchandran, MD, a medical oncologist and clinical associate professor of medicine at Stanford University, discusses considerations as patients with thoracic malignancies enter palliative care. Palliative care is the optimal supportive ca...

OCT: A Role in Monitoring Multiple Sclerosis?
https://www.medscape.com/viewarticle/778851

Feb 12th, 2013 - Active MS Is Associated With Accelerated Retinal Ganglion Cell/Inner Plexiform Layer Thinning Ratchford JN, Saidha S, Sotirchos ES, et al Neurology. 2013;80:47-54. Optical Coherence Tomography Optical coherence tomography (OCT) has improved the ab...

see more →